Search research articles
Contact Us
Filters
Showing results (1-10 of 24) with videos related to
Page
of 3
Sort By:
The European Journal of Neuroscience
|
October 1, 2018
The Linked Clinical Trials initiative (LCT) for Parkinson's disease
Patrik Brundin, Richard K Wyse
Journal of Parkinson'S Disease
|
July 20, 2016
Nilotinib - Differentiating the Hope from the Hype
Richard K Wyse, Patrik Brundin, Todd B Sherer
Frontiers in Neuroscience
|
April 5, 2021
Drug Repurposing for Parkinson's Disease: The International Linked Clinical Trials experience
Simon R W Stott, Richard K Wyse, Patrik Brundin
Progress in Brain Research
|
April 6, 2020
Novel approaches to counter protein aggregation pathology in Parkinson's disease
Simon R W Stott, Richard K Wyse, Patrik Brundin
Iranian Journal of Kidney Diseases
|
January 6, 2012
Cellular and molecular aspects of Goodpasture syndrome
Faris Q Alenzi, Mohamed L Salem, Fawwaz A Alenazi, et al.
Saudi Medical Journal
|
July 3, 2007
A close link between Fas, p53 and Apaf-1 in chronic myeloid leukemia
Faris Q Alenzi, Richard K Wyse, Waleed G Tamimi, et al.
Brain Communications
|
January 4, 2021
The Parkinson's Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures
Matthias Luz, Alan Whone, Niccolò Bassani, et al.
Journal of Parkinson'S Disease
|
June 21, 2021
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
Kevin McFarthing, Gary Rafaloff, Marco A S Baptista, et al.
Journal of Parkinson'S Disease
|
August 4, 2020
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing, Sue Buff, Gary Rafaloff, et al.
Journal of Parkinson'S Disease
|
May 9, 2022
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
Kevin McFarthing, Gary Rafaloff, Marco Baptista, et al.
Page
of 3
Search research articles
Search
Showing results (1-10 of 24) with videos related to
Sort By:
Page
of 3
The European Journal of Neuroscience
|
October 1, 2018
The Linked Clinical Trials initiative (LCT) for Parkinson's disease
Patrik Brundin, Richard K Wyse
Journal of Parkinson'S Disease
|
July 20, 2016
Nilotinib - Differentiating the Hope from the Hype
Richard K Wyse, Patrik Brundin, Todd B Sherer
Frontiers in Neuroscience
|
April 5, 2021
Drug Repurposing for Parkinson's Disease: The International Linked Clinical Trials experience
Simon R W Stott, Richard K Wyse, Patrik Brundin
Progress in Brain Research
|
April 6, 2020
Novel approaches to counter protein aggregation pathology in Parkinson's disease
Simon R W Stott, Richard K Wyse, Patrik Brundin
Iranian Journal of Kidney Diseases
|
January 6, 2012
Cellular and molecular aspects of Goodpasture syndrome
Faris Q Alenzi, Mohamed L Salem, Fawwaz A Alenazi, et al.
Saudi Medical Journal
|
July 3, 2007
A close link between Fas, p53 and Apaf-1 in chronic myeloid leukemia
Faris Q Alenzi, Richard K Wyse, Waleed G Tamimi, et al.
Brain Communications
|
January 4, 2021
The Parkinson's Disease Comprehensive Response (PDCORE): a composite approach integrating three standard outcome measures
Matthias Luz, Alan Whone, Niccolò Bassani, et al.
Journal of Parkinson'S Disease
|
June 21, 2021
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update
Kevin McFarthing, Gary Rafaloff, Marco A S Baptista, et al.
Journal of Parkinson'S Disease
|
August 4, 2020
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2020
Kevin McFarthing, Sue Buff, Gary Rafaloff, et al.
Journal of Parkinson'S Disease
|
May 9, 2022
Parkinson's Disease Drug Therapies in the Clinical Trial Pipeline: 2022 Update
Kevin McFarthing, Gary Rafaloff, Marco Baptista, et al.
Page
of 3